ICMR: Hydroxychloroquine could have side-effects

NEW DELHI: Healthcare workers who took anti-malaria drug hydroxychloroquine (HCQ) suffered from its side-effects like abdominal pain, nausea and hypoglycemia according to a study conducted by the Indian Council of Medical Research (ICMR).

ICMR head of epidemiology and communicable diseases, Dr R R Gangakhedkar said that “A study has been launched to know the side-effects of HCQ. We found that healthcare workers having an average age of 35 years took these drugs and 10% reported abdominal pain, 6% reported nausea and 1.3% reported hypoglycemia.”
“Around 22% of these healthcare workers also had other conditions like diabetes, cardiovascular diseases and blood pressure and therefore, probably out of fear, took HCQ as a preventive measure”, he further added.
“We are not doing a trial and we don’t have sufficient evidence base to do a trial. There will be about 480 patients who will be enrolled and it will go on for about 2.5 months,” Dr Gangakhedkar said.

ICMR is also researching to find out the other effects of HCQs.

  • Related Posts

    ‘Import of Refurbished Medical Devices’ Lobby has reared its Ugly Head

    Domestic Medical Device Leaders cry foul against move to do away with Policy Restrictions New Delhi:  The union government mandarins seem to be at it again, diametrically opposed to Prime…

    Indigenous Robotic Surgery is Mantra for Accessible Cancer Care in India

    Best in Class ‘Made in India’ Surgical Robot is proving Best Bet New Delhi: ‘Made in India’ best in class surgical robot SSiMantra is proving godsend for cancer patients in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory